Patent application EP16153966A (EP), filed 2016-02-02
Publication number: EP3202783A1
Title: ENGINEERED ANTIGEN PRESENTING CELLS AND USES THEREOF
Abstract: The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to enhance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and/or treatment of a cancer.
IPC codes: A61K  39/    00            A I
C07K  14/   705            A I
C07K  16/    32            A I
Claims: number: 1
text: A recombinant extra-cellular vesicle internalizing receptor (EVIR) comprising:
number: 2
text: An EVIR according to claim 1 wherein the extracellular antibody domain is a scFv.
number: 3
text: An EVIR according to claims 1 or 2, wherein the extracellular antibody domain comprises a sequence of an antibody, or a fragment thereof, specific for human epidermal growth factor receptor 2 (HER2).
number: 4
text: An EVIR according to claims 1 or 2, wherein the extracellular antibody domain comprises a sequence of an antibody, or a fragment thereof, specific for tyrosinase-related protein-1 (TYRP1), carcinoembryonic antigen (CEA), mesothelin, PMEL (gp100), gangliosides (GD2, GD3), or mucins.
number: 5
text: An EVIR according to any one of claims 1 to 3, wherein the extracellular antibody domain comprises a sequence selected from SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30 or a variant thereof.
number: 6
text: An EVIR according to any one of claims 1 to 5 wherein the proteinic domain is selected from SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40 and SEQ ID NO: 41 or a variant thereof.
number: 7
text: An EVIR according to any one of claims 1 to 6 comprising a cell membrane export domain comprising an IgK domain.
number: 8
text: An EVIR according to anyone of claims 1 to 3 or 5 to 7 comprising an amino acid sequence selected from a SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63 and SEQ ID NO: 64 or a variant thereof.
number: 9
text: An isolated nucleic acid sequence encoding an EVIR according to any one of claims 1 to 8.
number: 10
text: An isolated nucleic acid according to claim 9 comprising a sequence selected from SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74 and SEQ ID NO: 75 or a variant
number: 11
text: Anex vivo method of inducing expression of at least one EVIR according to any of claims 1 to 8, in an antigen-presenting cell (APC) or a stem/progenitor cell thereof, comprising the steps of:
number: 12
text: A method according to claim 11 wherein the vector comprises a nucleic acid sequence according to claim 10.
number: 13
text: An isolated antigen presenting cell (APC) or a stem or progenitor cell thereof expressing at least one EVIR according to any one of claims 1 to 8.
number: 14
text: Anex vivo method of preparing EVIR-expressing, TAAs-presenting cells, comprising the steps of:
number: 15
text: A pharmaceutical composition comprising at least one vector encoding at least one EVIR according to any of any one of claims 1 to 8 or cells according to claim 13 or cells obtainable from a method according to claims 11 or 14 and at least one pharmaceutically acceptable carrier, diluent or excipient thereof.
number: 16
text: A pharmaceutical composition according to claim 15 for use in the prevention and/or treatment of a cancer.
Office action: search_report, dated 2017-08-09
Prior art cited: ref_id: - WALDMANN ET AL., NAT MED, vol. 9, 2003, pages 269 - 277
ref_type: npl
severity: background
ref_id: - MILLER ET AL., CANCER CELL, vol. 27, no. 4, 2015, pages 439 - 49
ref_type: npl
severity: background
ref_id: - PALUCKA ET AL., NAT REV CANCER, vol. 12, no. 4, 2012, pages 265 - 77
ref_type: npl
severity: background
ref_id: - GARDNER ET AL., HUM VACCIN IMMUNOTHER, vol. 8, no. 4, 2012, pages 534 - 9
ref_type: npl
severity: background
ref_id: - KASTENMUELLER ET AL., NAT REV IMMUNOL., vol. 14, no. 10, 2014, pages 705 - 11
ref_type: npl
severity: background
ref_id: - GU ET AL., INTERN JOURNAL OF CANCER, vol. 136, 2015, pages E74 - 84
ref_type: npl
severity: background
ref_id: - BIGLARI ET AL., GENE THERAPY, vol. 13, 2006, pages 602 - 610
ref_type: npl
severity: background
ref_id: - WEI ET AL., CANCER RESEARCH, vol. 68, 2008, pages 3854 - 62
ref_type: npl
severity: background
ref_id: - AHMED ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 33, 2015, pages 1688 - 1696
ref_type: npl
severity: background
ref_id: - SCHONFELD ET AL., MOLECULAR THERAPY, vol. 23, 2015, pages 330 - 338
ref_type: npl
severity: background
ref_id: - HOLLIGER ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 1136
ref_type: npl
severity: background
ref_id: - ZHOU ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, 2011, pages 31676 - 31683
ref_type: npl
severity: background
ref_id: - MORGAN ET AL., MOL THER., vol. 18, no. 4, 2010, pages 843 - 51
ref_type: npl
severity: background
ref_id: - FRANKLIN ET AL., CANCER CELL, vol. 5, no. 4, 2004, pages 317 - 28
ref_type: npl
severity: background
ref_id: - AHMED ET AL., MOL THER., vol. 17, no. 10, 2009, pages 1779 - 87
ref_type: npl
severity: background
ref_id: - SAENGER ET AL., CANCER RES, vol. 68, no. 23, 2008, pages 9884 - 91
ref_type: npl
severity: background
ref_id: - SADELAIN ET AL., CANCER DISCOV, vol. 3, no. 4, 2013, pages 388 - 98
ref_type: npl
severity: background
ref_id: - VON HEIJNE ET AL., NAT REV MOL CELL BIOL., vol. 7, 2006, pages 909 - 18
ref_type: npl
severity: background
ref_id: - SQUADRITO ET AL., CELL REP, vol. 8, no. 5, 2014, pages 1432 - 46
ref_type: npl
severity: background
ref_id: - THERY ET AL.: "Curr Protoc Cell Biol", 2006, pages: 22
ref_type: npl
severity: background
ref_id: - KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131
ref_type: npl
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - DAVIS ET AL.: "Methods in Molecular Biology", 1995, MCGRAW-HILL PROFESSIONAL PUBLISHING
ref_type: npl
severity: background
ref_id: - "The Science and Practice of Pharmacy", LIPPINCOTT WILLIAMS & WILKINS
ref_type: npl
severity: background
ref_id: - AMENDOLA ET AL., NAT BIOTECHNOL, vol. 23, no. 1, 2005, pages 108 - 16
ref_type: npl
severity: background
ref_id: - SQUADRITO ET AL., CELL REP, vol. 1, no. 2, 2012, pages 141 - 54
ref_type: npl
severity: background
ref_id: - HOGQUIST ET AL., CELL, vol. 76, 1994, pages 17 - 27
ref_type: npl
severity: background
ref_id: - DE PALMA ET AL., METHODS IN ENZYMOLOGY, vol. 346, 2002, pages 514 - 529
ref_type: npl
severity: background
ref_id: - ZEELENBERG ET AL., JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950), vol. 187, 2011, pages 1281 - 1288
ref_type: npl
severity: background
ref_id: - KARSTEN MAHNKE ET AL: "The Dendritic Cell Receptor for Endocytosis, DEC-205, Can Recycle andEnhance Antigen Presentation via Major Histocompatibility ComplexClass II-positive Lysosomal Compartments", THE JOURNAL OF CELL BIOLOGY, 30 October 2000 (2000-10-30), pages 21 - 9525, XP055266759, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2185598/pdf/0007035.pdf> [retrieved on 20160418]
ref_type: npl
severity: background
ref_id: - KURT SCHÖNFELD ET AL: "Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor", MOLECULAR THERAPY, vol. 23, no. 2, 6 November 2014 (2014-11-06), GB, pages 330 - 338, XP055265087, ISSN: 1525-0016, DOI: 10.1038/mt.2014.219
ref_type: npl
severity: background
ref_id: - CLOTILDE THÉRY ET AL: "Membrane vesicles as conveyors of immune responses", NATURE REVIEWS IMMUNOLOGY, vol. 9, no. 8, 1 August 2009 (2009-08-01), pages 581 - 593, XP055018445, ISSN: 1474-1733, DOI: 10.1038/nri2567
ref_type: npl
severity: background
ref_id: - LAURA ANN MULCAHY ET AL: "Routes and mechanisms of extracellular vesicle uptake", JOURNAL OF EXTRACELLULAR VESICLES, vol. 11, no. 0, 4 August 2014 (2014-08-04), pages 1093, XP055266760, DOI: 10.1016/j.exphem.2010.01.002
ref_type: npl
severity: background
ref_id: - MARÍA YÁÑEZ-MÓ ET AL: "Biological properties of extracellular vesicles and their physiological functions", JOURNAL OF EXTRACELLULAR VESICLES, vol. 10, no. 0, 14 May 2015 (2015-05-14), pages 261, XP055266766, DOI: 10.3402/jev.v4.27066
ref_type: npl
severity: background
ref_id: - Karsten Mahnke ET AL, "The Dendritic Cell Receptor for Endocytosis, DEC-205, Can Recycle andEnhance Antigen Presentation via Major Histocompatibility ComplexClass II-positive Lysosomal Compartments", The Journal of Cell Biology, (20001030), pages 21 - 9525, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2185598/pdf/0007035.pdf, (20160418), XP055266759 [A] 1-16 * abstract * * page  673  - page  675 *
ref_type: npl
severity: background
ref_id: - KURT SCHÖNFELD ET AL, "Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor", MOLECULAR THERAPY, GB, (20141106), vol. 23, no. 2, doi:10.1038/mt.2014.219, ISSN 1525-0016, pages 330 - 338, XP055265087 [A] 1-16 * abstract *
ref_type: npl
severity: background
ref_id: - CLOTILDE THÉRY ET AL, "Membrane vesicles as conveyors of immune responses", NATURE REVIEWS IMMUNOLOGY, (20090801), vol. 9, no. 8, doi:10.1038/nri2567, ISSN 1474-1733, pages 581 - 593, XP055018445 [A] 1-16 * the whole document *
ref_type: npl
severity: background
ref_id: - LAURA ANN MULCAHY ET AL, "Routes and mechanisms of extracellular vesicle uptake", JOURNAL OF EXTRACELLULAR VESICLES, (20140804), vol. 11, no. 0, doi:10.1016/j.exphem.2010.01.002, page 1093, XP055266760 [A] 1-16 * abstract * * page  2  - page  6 * * table II *
ref_type: npl
severity: background
ref_id: - MARÍA YÁÑEZ-MÓ ET AL, "Biological properties of extracellular vesicles and their physiological functions", JOURNAL OF EXTRACELLULAR VESICLES, (20150514), vol. 10, no. 0, doi:10.3402/jev.v4.27066, page 261, XP055266766 [A] 1-16 * the whole document *
ref_type: npl
severity: background
Final disposition: pending (2017-08-09)